Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic

Stephen Rittenhouse; Christine Singley; Jennifer Hoover; Roni Page; David Payne

doi:10.1128/AAC.00183-06

Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic

Antimicrob Agents Chemother. 2006 Nov;50(11):3886-8. doi: 10.1128/AAC.00183-06.

Authors

Stephen Rittenhouse¹, Christine Singley, Jennifer Hoover, Roni Page, David Payne

Affiliation

¹ Department of Microbiology Research, MMPD CEDD, GlaxoSmithKline Pharmaceuticals, 1250 S. Collegeville Rd, Collegeville, PA 19426-0989, USA. [email protected]

Abstract

The effect of topically applied retapamulin ointment was evaluated using various dosing regimens in the Staphylococcus aureus and Streptococcus pyogenes wound infection model. Retapamulin (1%, wt/wt) was efficacious using twice-daily (b.i.d.) applications for 4 or 5 days. These data underpinned the decision to evaluate 1% retapamulin b.i.d. in clinical trials.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Topical
Animals
Anti-Bacterial Agents / administration & dosage
Anti-Bacterial Agents / therapeutic use
Anti-Infective Agents, Local / administration & dosage*
Anti-Infective Agents, Local / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Colony Count, Microbial
Diterpenes
Drug Resistance, Bacterial
Methicillin Resistance
Mice
Mupirocin / administration & dosage
Mupirocin / therapeutic use
Ointments
Staphylococcal Infections / drug therapy
Staphylococcal Infections / microbiology
Staphylococcus aureus / drug effects
Surgical Wound Infection / drug therapy*
Surgical Wound Infection / microbiology

Substances

Anti-Bacterial Agents
Anti-Infective Agents, Local
Bridged Bicyclo Compounds, Heterocyclic
Diterpenes
Ointments
retapamulin
Mupirocin